David Lebovitz
Stock Analyst at Citigroup
(3.28)
# 1,028
Out of 5,157 analysts
91
Total ratings
66.67%
Success rate
8.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $527 → $583 | $322.38 | +80.84% | 33 | Sep 2, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $82 → $78 | $60.89 | +28.10% | 4 | May 2, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $378 → $469 | $432.78 | +8.37% | 4 | Feb 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $37.35 | +98.13% | 2 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $90.93 | -58.21% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $68.56 | -75.20% | 5 | Oct 27, 2023 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $93.01 | -41.94% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $75.66 | -53.74% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $3.43 | +395.63% | 11 | Apr 30, 2021 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | $12 → $11 | $3.70 | +197.30% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $240.52 | -17.26% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $510 → $480 | $8.23 | +5,732.32% | 2 | Nov 3, 2020 |
Alnylam Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $527 → $583
Current: $322.38
Upside: +80.84%
BioMarin Pharmaceutical
May 2, 2025
Maintains: Neutral
Price Target: $82 → $78
Current: $60.89
Upside: +28.10%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378 → $469
Current: $432.78
Upside: +8.37%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $37.35
Upside: +98.13%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $90.93
Upside: -58.21%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $68.56
Upside: -75.20%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $93.01
Upside: -41.94%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $75.66
Upside: -53.74%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $3.43
Upside: +395.63%
Ironwood Pharmaceuticals
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $3.70
Upside: +197.30%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $240.52
Upside: -17.26%
Nov 3, 2020
Maintains: Overweight
Price Target: $510 → $480
Current: $8.23
Upside: +5,732.32%